PHARMACOVIGILANCE IN PRACTICE: ASSESSING ADVERSE DRUG REACTIONS IN TERTIARY CARE HOSPITAL CENTRAL INDIA

AVINA KHARAT; POOJA SOLANKI MISHRA; MEGHNA SHINDE; ANERI PATEL; NARLAPATI VIGNAN

doi:10.22159/ijpps.2025v17i2.52982

Authors

AVINA KHARAT Department of Pharmacology, MGM Medical College, Indore, Madhya Pradesh, India https://orcid.org/0009-0000-5502-960X
POOJA SOLANKI MISHRA Department of Pharmacology, MGM Medical College, Madhya Pradesh, India https://orcid.org/0009-0000-5502-960X
MEGHNA SHINDE Department of Pharmacology, MGM Medical College, Indore, Madhya Pradesh, India https://orcid.org/0009-0000-5502-960X
ANERI PATEL Department of Pharmacology, MGM Medical College and M. Y. Hospital, Indore, Madhya Pradesh, India https://orcid.org/0009-0000-5502-960X
NARLAPATI VIGNAN Department of Pharmacology, MGM Medical College and M. Y. Hospital, Indore, Madhya Pradesh, India https://orcid.org/0009-0007-4511-625X

DOI:

https://doi.org/10.22159/ijpps.2025v17i2.52982

Keywords:

Adverse drug reaction monitoring, Healthcare awareness, Drug safety, Causality, Pharmacovigilance

Abstract

Objective: Our study aimed to evaluate the frequency, severity, and causality of ADRs reported at the ADR Monitoring Centre, Department of Pharmacology, MGM Medical College, Indore, to improve drug safety practices.

Methods: A retrospective study at the ADR Monitoring Centre in Indore analyzed suspected ADR Reporting Forms from the past six months. The analysis focused on ADR frequency, severity, and causality, categorized using the World Health Organization (WHO) causality assessment scale.

Results: Over six months, 502 ADR forms were reported at Maharaja Yashwant Rao Hospital, Indore, with males (25-55 years) accounting for 50% of the cases. The psychiatry department reported the most ADRs (57.5%), followed by pediatrics (12.1%) and gynecology (9.7%). Commonly implicated drug classes were antipsychotics, antibiotics, and anticonvulsants. Valproate (14%), ceftriaxone (8%), and olanzapine (6%) were frequently involved drugs. About 52.6% of ADRs were certain, and 25% were probable in causality analysis.

Conclusion: Monitoring and reporting ADRs are crucial in healthcare. Raising awareness about ADR reporting among doctors and patients can promote safer drug use, reduce associated ADR-related morbidity, ease the treatment burden on patients, and enhance their quality of life.

Downloads

Download data is not yet available.

References

Brahmbhatt SV, Rajput M. Pharmacovigilance. Int J Health Sci. 2022;6(6):18–21.

Abbood MK, Khalaf HAA, Abudlqader EH, Taghi HS, Al-Temimi AA. Scope of pharmacovigilance: A comprehensive review. Chem Sci Int J. 2022;29:29–39.

Zatovkanukova P, Slíva J. The position and importance of pharmacovigilance in the Czech Republic and the world. Vnitrni Le Karr Stvii. 2022;68(3):E10–5.

Mueller M, Lewis D, Alexe A. The evolution of pharmacovigilance ecosystems: Does Moore’s law invite the use of Ockham’s razor? Authorea. 2022;89.

Bhardwaj K, Alam R, Pandeya A, Sharma PK. Artificial intelligence in pharmacovigilance and COVID-19. Curr Drug Saf. 2023;18(1):5–14.

Fornasier G, Francescon S, Leone R, Baldo P. A historical overview of pharmacovigilance. Int J Clin Pharm. 2018;40(5):744–7.

Caron J, Rochoy M, Gaboriau L, Gautier S. Histoire de la pharmacovigilance. Thérapie. 2016;71(2):123–8.

Ibara M, Richesson RL. Back to the future: The evolution of pharmacovigilance in the age of digital healthcare. Computers in Health Care. 2019:433–51.

Elshafie S, Zaghloul I, Roberti AM. Pharmacovigilance in developing countries (Part I): Importance and challenges. Int J Clin Pharm. 2017;40(5):758–63.

Sen M, Singh A, Misra M. Retrospective analysis of adverse drug reactions reported at the ADR monitoring centre under PvPI in a tertiary care hospital. Int J Basic Clin Pharmacol. 2018;7(4):303.

Omar IH, Harris E. The use of social media in ADR monitoring and reporting. J Pharmacovigil. 2016;4(6):06.

Kaur I, Kalaiselvan V, Kumar R, Mishra P. Reporting of adverse drug reactions by pharmacists in the Pharmacovigilance Programme of India: A perspective. Curr Overview Pharm Sci. 2023;7(2):128–34.

Brahmbhatt S, Rajput M. Pharmacovigilance: Significance and challenges. Int J Health Sci. 2022;5(6):860–3.

McAnaney BT, Bandon WE, Stephen DK, Mattson TL, Patrick KP, Testa JK, McNamara MM. Methods and systems for managing invention disclosures. Google Patents. US6654767B2. 2000.

Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through the outcome of the Pharmacovigilance Programme of India. Indian J Pharmacol. 2021;53(2):143.

World Health Organization. Guidelines for the regulatory assessment of medicinal products for use in self-medication. WHO/EDM/QSM/00.1. 2000. Available from: https://www.scirp.org/reference/referencespapers?referenceid=1912686.

Buabeng RO, Dsane-Aidoo P, Asamoah YK, Bandoh DA, Boahen YA, Sabblah GT. Under-reporting of adverse drug reactions: Surveillance system evaluation in Ho Municipality of the Volta Region, Ghana. PLOS ONE. 2023;18:e0291482.

Alghazwani Y, Alqahtani AMM, Alshuraymi MK, Assiri IM, Shuflut AA, Krishnaraju V. The perspective of pharmacists on pharmacovigilance and adverse drug reaction reporting in Asir region, Saudi Arabia. J Pharm Pract. 2023;27(7):1667–80.

Aagaard L, Strandell J, Melskens L, Petersen PSG, Hansen EH. Global patterns of adverse drug reactions over a decade. Drug Saf. 2012;35(12):1171–82.

Shchory MP, Goldstein LH, Arcavi L, Shihmanter R, Berkovitch M, Levy A. Increasing adverse drug reaction reporting—How can we do better? PLOS ONE. 2020;15:e0235591.

Yawson AA, Abekah-Nkrumah G, Okai GA, Ofori CG. Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana. Ther Adv Drug Saf. 2022;13(1):204209862211164.

Sharma M, Baghel R, Thakur S, Adwal SK. Surveillance of adverse drug reactions at an ADR monitoring centre in Central India: A 7-year surveillance study. BMJ Open. 2021;11:e052737.

Raveendran N, Krishna SK, Rai M, Ravindran A, Chandrashekar R. Precedence of cognizant adverse drug reactions (ADRs) reporting in a South Indian tertiary care hospital: A prospective study. Indian J Pharm Pharmacol. 2016;3(2):39–43.

Patel JJ, Shah M, Patel P, Gandhi A, Desai M. Knowledge, attitude, and practice among consumers about adverse drug reaction reporting. Int J Basic Clin Pharmacol. 2019;8(8):1776–80.

Khanna S, Singh DK, Shankar P, Tutu S, Lakhani P, Dixit RK. A survey to assess knowledge, attitude, and practices among doctors about pharmacovigilance. World J Pharm Sci. 2015;3(12):2292–2514.

Joshi D, Gupta S, Singh TG, Parashar A, Singh SK. A qualitative evaluation of ADR reporting in India: Non-regulatory confronts and their possible solutions. ECS Trans. 2022;107:6763–80.

Mascolo A, Scavone C, Sessa M, Di Mauro G, Cimmaruta D, Orlando V, et al. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacol Res. 2017;123:122–9.

Sunitha M, Parvathy S. A study of agreement between WHO-Uppsala Monitoring Centre criteria, Naranjo algorithm, and Liverpool algorithm for causality assessment of adverse drug reactions. Int J Pharm Pharm Sci. 2021;20(2):120–5.

Da Silva RF. Causality assessment in pharmacovigilance: Principles and fundamentals of causal inference. Rev Salus. 2022;4(3):45–50.

Mascolo A, Scavone C, Sessa M, Di Mauro G, Cimmaruta D, Orlando V. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacol Res. 2017;123:122–9.

Padmavathi S, Manimekalai K, Ambujam S. Causality, severity, and preventability assessment of adverse cutaneous drug reaction: A prospective observational study in a tertiary care hospital. J Clin Diagn Res. 2013;7(12):2765–7.

Ganjikunta RK, Kadali RP, Arora T, Chalivendra P. Evaluation of cutaneous adverse drug reactions reported in a teaching hospital of Coastal Andhra. Biomed Pharmacol J. 2023;16(2):1113–9.

Sivakumar V, D AC, Devashree V, Kaviya S, Krishnan T. Analysis of voluntarily reported adverse drug reactions in a tertiary care hospital. Int J Basic Clin Pharmacol. 2023;12(3):406–9.

Pathak AK, Kumar M, Dokania S, Mohan L, Dikshit H. A retrospective analysis of reporting of adverse drug reactions in a tertiary care teaching hospital: One-year survey. J Clin Diagn Res. 2016;10(7):1621–3.

Modi A, Desai M, Shah S, Shah B. Analysis of cutaneous adverse drug reactions reported at the regional ADR monitoring center. Indian J Dermatol. 2019;64(4):250–3.

Jindal A, Brar BK, Kumar R, Kumar S, Sidhu K, Kaur A. Pattern of adverse drug reactions with chemotherapeutic drugs in a tertiary care hospital of North India: A retrospective study. Int J Basic Clin Pharmacol. 2023;12(2):236–9.

Gurpoonam J, Kumar GS, Sandeep K, Shobhna K, Sandeep K. Cutaneous adverse drug reactions: A one-year prospective study. Iranian J Dermatol. 2017;20(4):103–12.

Kaur K, Kanwal P, Goyal P, Singh P, Yakhmi S, Jain S. Spontaneous adverse drug reaction monitoring in a tertiary care centre. Curr Drug Saf. 2020;15(3):215–21.

Princy E, Olisha DM, Dhawal S, Jitendra V. A cross-sectional pharmacovigilance study on adverse drug reaction in a tertiary care teaching hospital. Asian J Pharm Clin Res. 2022;15(1):103–6.

Patil SB, Gade R, Raghuveer B, Venkatarao Y, Yamini. An annual retrospective analysis of adverse drug reactions reported at the ADR monitoring center, Nalgonda. Natl J Physiol Pharm Pharmacol. 2021;12(1):1–5.

Giri K, Palandurkar K, Giri R, Agrawal UK. Asian J Pharm Clin Res. 2022;15(1):51–6.